Myeloid Neoplasia

Myeloid Neoplasia

A collection of features and news articles published in ASH Clinical News related to myeloid neoplasia.

WIB_icon

Researchers Identify Cancer Gene Mutations Linked to Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a susbset do not...

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology Association suggest that combining an IDH inhibitor (ivosidenib or...

Cardiac Biomarkers Predict Quality of Life in Patients With Light-Chain Amyloidosis

In a study presented at the 23rd Congress of the European Hematology Association, researchers demonstrated a relationship between B-type natriuretic peptide (BNP) and N-terminal...

Bispecific Antibody AMV564 Active in Relapsed and Refractory AML

Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed and refractory acute myeloid leukemia (AML) with a tolerable...

Higher-Dose Daunorubicin No More Effective Than Lower Doses in AML

Escalating daunorubicin doses from 60 mg/m2 to 90 mg/m2 in a 7+3 induction regimen consisting of daunorubicin and cytarabine did not increase response rates...

FDA Approves Second Filgrastim Biosimilar

The U.S. Food and Drug Administration (FDA) has approved filgrastim-aafil, a biosimilar version of filgrastim, making it the second approved biosimilar for this agent....

FDA Approves IDH Inhibitor for Patients with AML

The U.S. Food and Drug Administration (FDA) has approved ivosidenib as the first IDH1 inhibitor for patients with relapsed or refractory acute myeloid leukemia...

Positive Results With Ivosidenib in Patients With High-Risk, Previously Treated AML

Treatment with ivosidenib, a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor, led to durable remissions among people with relapsed or refractory, IDH1-mutated acute myeloid leukemia...

Can Pevonedistat Improve Azacitidine’s Activity in Older Patients With AML?

Adding pevonedistat, a first-in-class inhibitor of the NEDD8-activating enzyme (NAE), to azacitidine led to responses in patients with acute myeloid leukemia (AML), according to...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...
Advertisement

Current Issue

August 2018, Volume 4, Issue 10

This issue features a look at direct-to-consumer pharmaceutical advertising, advice to graduating hematologists, and more.